Symptomatic remission and cognitive impairment in first-episode schizophrenia: A prospective 3-year follow-up study

Journal of Clinical Psychiatry

Volumn 74, Issue 11, 2013, Pages

  Chang, Wing Chung ^a   Hui, Christy Lai Ming ^a   Wong, Gloria Hoi Yan ^a   Chan, Sherry Kit Wa ^a   Lee, Edwin Ho Ming ^a   Chen, Eric Yu Hai ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DSM-IV; FEMALE; FOLLOW UP; HIGH ROYDS EVALUATION OF NEGATIVITY SCALE; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MIDDLE AGED; NEGATIVE SYNDROME; OCCUPATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; REMISSION; SCHIZOPHRENIA; TREATMENT OUTCOME; VERBAL MEMORY; YOUNG ADULT;

EID: 84889246918     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08355     Document Type: Article

References (65)

1. Elvevo B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1-21. doi:10.1615/ CritRevNeurobiol.v14.i1.10 PubMed
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426-445. doi:10.1037/0894-4105.12.3.426 PubMed
3. Mesholam-Gately RI, Giuliano AJ, Goff KP, et al. Neurocognition in firstepisode schizophrenia: a meta-analytic review. Neuropsychology. 2009;23(3):315-336. doi:10.1037/a014708 PubMed
4. Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med. 2011;41(2):225-241. doi:10.1017/S032917101042 PubMed
5. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26(1):119-136. doi:10.1093/oxfordjournals. schbul.a03430 PubMed
6. Allott K, Liu P, Proffitt TM, et al. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res. 2011;125(2-3):221-235. doi:10.1016/j.schres.2010.1.01 PubMed
7. Verdoux H, Liraud F, Assens F, et al. Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of firstadmitted patients. Schizophr Res. 2002;56(1-2):149-159. doi:10.1016/S0920-964(01)025-0 PubMed
8. Addington J, Saeedi H, Addington D. The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome. Schizophr Res. 2005;78(1):35-43. doi:10.1016/j.schres.205.05.08 PubMed
9. Bodnar M, Malla A, Joober R, et al. Cognitive markers of short-term clinical outcome in first-episode psychosis. Br J Psychiatry. 2008;193(4):297-304. doi:10.192/bjp.bp.107.040410 PubMed
10. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449. doi:10.176/api.ajp.162.3.41 PubMed
11. Lambert M, Karow A, Leucht S, et al. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci. 2010;12(3):393-407. PubMed
12. Chang WC, Chan TCW, Chen ESM, et al. The concurrent and predictive validity of symptomatic remission criteria in first-episode schizophrenia. Schizophr Res. 2013;143(1):107-115. doi:10.1016/j.schres.2012.10.016 PubMed
13. Lasser RA, Nasrallah H, Helldin L, et al. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr Res. 2007;96(1-3):223-231. doi:10.1016/j.schres.207.05.03 PubMed
14. Helldin L, Kane JM, Karilampi U, et al. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res. 2006;40(8):738-745. doi:10.1016/j.jpsychires.206.07.05 PubMed
15. Bankole A, Cohen CI, Vahia I, et al. Symptomatic remission in a multiracial urban population of older adults with schizophrenia. Am J Geriatr Psychiatry. 2008;16(12):966-973. doi:10.1097/JGP.0b013e31818af801 PubMed
16. Eberhard J, Levander S, Lindstro E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry. 2009;50(3):200-208. doi:10.1016/j.compsych.208.08.010 PubMed
17. Hofer A, Bodner T, Kaufmann A, et al. Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol Med. 2011;41(10):2131-2139. doi:10.1017/S03291710353 PubMed
18. Yun Y, Hwang SSH, Kim Y, et al. Impairments in executive functioning in patients with remitted and non-remitted schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1148-1154. doi:10.1016/j.pnpbp.201.03.018 PubMed
19. Braw Y, Benozio A, Levkovitz Y. Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia. Schizophr Res. 2012;142(1-3):122-128. doi:10.1016/j.schres.2012. 10.01 PubMed
20. Auslander LA, Jeste DV. Sustained remission of schizophrenia among community-dwelling older outpatients. Am J Psychiatry. 2004;161(8):1490-1493. doi:10.176/api.ajp.161.8.1490 PubMed
21. Buckley PF, Harvey PD, Bowie CR, et al. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res. 2007;94(1-3):99-106. doi:10.1016/j.schres.206.12.032 PubMed
22. Emsley R, Rabinowitz J, Medori R; Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89(1-3):129-139. doi:10.1016/j.schres. 206.09.013 PubMed
23. Li CT, Su TP, Chou YH, et al. Symptomatic resolution among Chinese patients with schizophrenia and associated factors. J Formos Med Assoc. 2010;109(5):378-388. doi:10.1016/S0929-646(10)606-6 PubMed
24. Brissos S, Dias VV, Balanz-Martinez V, et al. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129(2-3):133-136. doi:10.1016/j.schres.201.04.01 PubMed
25. Meesters PD, Comijs HC, de Haan L, et al. Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia. Schizophr Res. 2011;126(1-3):237-244. doi:10.1016/j.schres.2010. 09.03 PubMed
26. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479. doi:10.176/api.ajp.161.3.473 PubMed
27. Bodnar M, Achim AM, Malla AK, et al. Functional magnetic resonance imaging correlates of memory encoding in relation to achieving remission in first-episode schizophrenia. Br J Psychiatry. 2012;200(4):300-307. doi:10.192/bjp.bp.1.098046 PubMed
28. Ventura J, Subotnik KL, Guzik LH, et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res. 2011;132(1):18-23. doi:10.1016/j.schres.201.06.025 PubMed
29. Chang WC, Hui CLM, Tang JYM, et al. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res. 2011;133(1-3):22-28. doi:10.1016/j.schres.201.09.06 PubMed
30. Chang WC, Hui CL, Tang JY, et al. Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study. Psychol Med. 2012;1-11. doi:10.1017/ S0329171202838 PubMed
31. Chang WC, Chan SSM, Chung DWS. Diagnostic stability of functional psychosis: a systematic review. Hong Kong J Psychiatry. 2009;19(1):30-41.
32. Chang WC, Pang SLK, Chung DWS, et al. Five-year stability of ICD-10 diagnoses among Chinese patients presented with first-episode psychosis in Hong Kong. Schizophr Res. 2009;115(2-3):351-357. doi:10.1016/j.schres.209.09.037 PubMed
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
34. So E, Kam I, Leung CM, et al. The Chinese-bilingual SCID-I/P Project: Stage 1: reliability for mood disorders and schizophrenia. Hong Kong J Psychiatry. 2003;13(1):7-18.
35. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470-484. doi:10.1093/schbul/8.3.470 PubMed
36. Cassidy CM, Norman R, Manchanda R, et al. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull. 2010;36(5):1001-1008. doi:10.1093/schbul/sbp07 PubMed
37. Honer H, Riecher-Rosler A, Hambrecht M, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res. 1992;6(3):209-223. doi:10.1016/0920-964(92)904-O PubMed
38. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261 PubMed
39. Mortimer AM, McKenna PJ, Lund CE, et al. Rating of negative symptoms using the High Royds Evaluation of Negativity (HEN) scale. Br J Psychiatry. 1989;155(suppl 7):89-91. PubMed
40. Chen EYH, Lam LCW, Chen RYL, et al. Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. Br J Psychiatry. 1996;168(2):227-233. doi:10.192/bjp.168.2.27 PubMed
41. World Health Organization. WHO Psychiatric Disability Assessment Schedule (WHO/DAS). Geneva, Switzerland: World Health Organization; 1988.
42. Hong Kong Psychological Society. The Wechsler Memory Scale-Revised (Cantonese version). Hong Kong, China: Hong Kong Psychological Society; 1989.
43. Hong Kong Psychological Society. The Wechsler Adult Intelligence Scale- Revised (Cantonese version). Hong Kong, China: Hong Kong Psychological Society; 1989.
44. Nelson HE. A modified card sorting test sensitive to frontal lobe defects. Cortex. 1976;12(4):313-324. PubMed
45. Atkins M, Burgess A, Bottomley C, et al. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull. 1997;21(4):224-226. doi:10.192/pb.21.4.24
46. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667. doi:10.408/JCP.v64n0607 PubMed
47. Chen EYH, Hui CLM, Dunn ELW, et al. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res. 2005;77(1):99-104. doi:10.1016/j.schres.205.02.020 PubMed
48. Helldin L, Kane JM, Karilampi U, et al. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007;93(1-3):160-168. doi:10.1016/j.schres.207.01.014 PubMed
49. Henry LP, Amminger GP, Harris MG, et al. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. J Clin Psychiatry. 2010;71(6):716-728. doi:10.408/JCP.08m04846yel PubMed
50. Addington J, Addington D. Symptom remission in first episode patients. Schizophr Res. 2008;106(2-3):281-285. doi:10.1016/j.schres.208.09.014 PubMed
51. Ucok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res. 2011;189(1):33-37. doi:10.1016/j.psychres.2010.1.013 PubMed
52. Bodnar M, Malla AK, Joober R, et al. Neural markers of early remission in first-episode schizophrenia: a volumetric neuroimaging study of the parahippocampus. Psychiatry Res. 2012;201(1):40-47. doi:10.1016/j.pscychresns. 201.07.012 PubMed
53. Peuskens J, Kaufman L, Van Vleymen B. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. Schizophr Res. 2007;95(1-3):169-173. doi:10.1016/j.schres.207.05.035 PubMed
54. Cirillo MA, Seidman LJ. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev. 2003;13(2):43-77. doi:10.1023/A:1023870821631 PubMed
55. Moritz S, Krausz M, Gottwalz E, et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology. 2000;33(1):48-51. doi:10.159/02919 PubMed
56. Joober R, Rouleau GA, Lal S, et al. Neuropsychological impairments in neuroleptic-responder vs -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res. 2002;53(3):229-238. doi:10.1016/S0920-964(01)0279-1 PubMed
57. Tulving E, Markowitsch HJ. Episodic and declarative memory: role of the hippocampus. Hippocampus. 1998;8(3):198-204. doi:10.102/(SICI)1098-1063(198)8: 3<198:AID-HIPO2>3.0.CO;2-G PubMed
58. Bodnar M, Malla AK, Czechowska Y, et al. Neural markers of remission in first-episode schizophrenia: a volumetric neuroimaging study of the hippocampus and amygdala. Schizophr Res. 2010;122(1-3):72-80. doi:10.1016/j.schres.2010.06. 013 PubMed
59. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975-983. doi:10.101/archpsyc. 62.9.975 PubMed
60. Oosthuizen P, Emsley RA, Keyter N, et al. Duration of untreated psychosis and outcome in first-episode psychosis: perspective from a developing country. Acta Psychiatr Scand. 2005;111(3):214-219. doi:10.1/j.160-047.204.048.x PubMed
61. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003;33(1):97-110. doi:10.1017/ S032917020675X PubMed
62. Clarke M, Whitty P, Browne S, et al. Untreated illness and outcome of psychosis. Br J Psychiatry. 2006;189(3):235-240. doi:10.192/bjp.bp.105.014068 PubMed
63. Jeppesen P, Petersen L, Thorup A, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008;38(8):1157-1166. doi:10.1017/ S032917080349 PubMed
64. Pajonk FG, Wobrock T, Gruber O, et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry. 2010;67(2):133-143. doi:10.101/archgenpsychiatry.209.193 PubMed
65. Eack SM, Hogarty GE, Cho RY, et al. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry. 2010;67(7):674-682. doi:10.101/archgenpsychiatry.2010.63